bluebird bio, Inc.(BLUE)

Description: bluebird bio, Inc., a clinical-stage biotechnology company, focuses on the development, manufacture, and marketing of therapies to treat various human diseases. Its product candidates include Lenti-D to treat patients with childhood cerebral adrenoleukodystrophy (ALD), a hereditary neurological disorder, as well as for the treatment of adult cerebral ALD; and CAR T cells products for treating oncology diseases. The company's product candidates also comprise LentiGlobin vector for the treatment of ß-thalassemia, a hereditary blood disorder; and sickle cell diseases. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

---

Keywords: Medicine Biotechnology Rare Diseases Medical Genetics Summit Dystrophy Human Diseases Childhood Sickle Cell Disease Genetic Genealogy Thalassemia Oncology Diseases Iglo Leukodystrophy

---

Home Page: www.bluebirdbio.com

BLUE Technical Analysis

60 Binney Street
Cambridge, MA 02142
United States
Phone: 339 499 9300

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)